Infantile Spasm Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies-Jazz Pharmaceuticals, Marinus Pharmaceuticals, Takeda

Infantile Spasm Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies-Jazz Pharmaceuticals, Marinus Pharmaceuticals, Takeda
DelveInsight Business Research LLP
DelveInsight’s “Infantile Spasm Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Infantile Spasm, historical and forecasted epidemiology as well as the Infantile Spasm market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Infantile Spasm Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Infantile Spasm, historical and forecasted epidemiology as well as the Infantile Spasm market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Infantile Spasm market report provides current treatment practices, emerging drugs, Infantile Spasm market share of the individual therapies, and current and forecasted Infantile Spasm market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Infantile Spasm treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Infantile Spasm market.

Some of the Key Facts of the Infantile Spasm Market Report:

  • Among children, less than 10 years of age, the annual prevalence of infantile spasms is 0.14 to 0.19 per 1000. The peak age at the onset of spasms is 4 to 6 months, and there appears to be a slight excess of male cases. The etiology of infantile spasms is unknown for 40% to 50% of affected children.

  • Infantile spasm (IS) is a unique and rare disorder with an incidence of 1.6 to 4.5 per 10,000 live births; this is roughly 2000 to 2500 new cases in the United States per year. The age of onset spans from the first week of life to 4.5 years of life with an average age of onset being 3 to 7 months of age.

  • Most estimates of the incidence of infantile spasms are between 0.25 and 0.42 per 1000 live births per year.

 Key Benefits of the Infantile Spasm Market Report

  • The report covers the descriptive overview of Infantile Spasm, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

  • Comprehensive insight has been provided into the Infantile Spasm epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Infantile Spasm is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of the Infantile Spasm market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Infantile Spasm market

Got queries? Click here to know more about the Infantile Spasm Market Landscape

Infantile Spasm Market Overview

Infantile spasms are an age-specific epileptic disorder of infancy and early childhood. Children with infantile spasms typically exhibit epileptic spasms along with the electroencephalographic (EEG) pattern known as hypsarhythmia. Infantile spasms were described first by West in 1841. The triad of spasms, arrest of psychomotor development, and hypsarhythmia is known as West syndrome.

Infantile Spasm Market Epidemiological Segmentation 

  • Infantile Spasm prevelant cases 

  • Infantile Spasm incident cases 

  • Infantile Spasm diagnosed cases 

  • Infantile Spasm treatment cases 

Infantile Spasm Market Outlook 

The Infantile Spasm market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Infantile Spasm market trends by analyzing the impact of current Infantile Spasm therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Infantile Spasm market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Infantile Spasm market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Infantile Spasm market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Infantile Spasm Market Landscape

Infantile Spasm Market Key Companies

  • Jazz Pharmaceuticals 

  • Marinus Pharmaceuticals 

  • Takeda 

  • Oveda Pharmaceuticals 

  • And many others 

Infantile Spasm Market Key Therapies 

  • Tricaprilin

  • GWP42003-P

  • Vigabatrin

  • TAK-935

And many others 

Table of Contents 

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of Infantile Spasm Market  

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Infantile Spasm Market Emerging Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Market Access and Reimbursement of Therapies

  12.  Appendix

  13.  Infantile Spasm Market Report Methodology

  14.  DelveInsight Capabilities

  15.  Disclaimer

  16.  About DelveInsight

Click here to read more about Infantile Spasm Market Landscape

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: